GE HealthCare Adds Two AI Features to Its Vscan Air Handheld Ultrasound System
Key Facts
On November 3, 2026, GE HealthCare announced the addition of two AI-enabled features to its Vscan Air handheld ultrasound system: Lung Guidance and Auto AS. The first guides users as they acquire lung images, while the second analyzes echocardiogram images to help assess the likelihood of moderate-to-severe aortic stenosis. The company said the tools are part of its efforts to expand point-of-care screening and assessment capabilities, where specialists conduct examinations near the patient. Carly Yoder, the company's chief executive officer of ultrasound and advanced visualization solutions, said they are "designed to shorten the distance between an initial physical assessment and a clear next step." The announcement brings lung scan guidance and support for cardiac assessment together on one handheld device.
Lung Guidance directs users to the probe positions and anatomical landmarks needed to perform a standard 8-zone lung ultrasound protocol. According to the company, the software supports the detection and scoring of B-lines, then organizes the findings in a report to help specialists present what they observed. It also includes a feature that automatically saves a clip when predefined image-quality and required-landmark criteria are met. The company said this workflow aims to standardize image acquisition and make it easier to organize findings within the examination. These functions position the software as an aid in performing the scan and documenting its outputs.
The company provided a descriptive indicator of image-acquisition performance, saying non-expert lung ultrasound users achieved a 95.2% success rate in obtaining scans of diagnostic quality. The corresponding rate among expert users was 96.8% in the same evaluation. The company statement did not specify when the evaluation took place and described it as descriptive. The result places the two groups side by side, but remains tied to scan acquisition under the measure cited by the company. The company presented the figures in the context of assessing users' ability to obtain suitable images, not as patient treatment outcomes.
Auto AS analyzes two-dimensional echocardiogram images captured with the Vscan Air SL and provides a visual estimate of the likelihood of moderate-to-severe aortic stenosis, along with a confidence score. The analysis requires at least two compatible views from those supported by the tool. The company says it is intended to support early assessment, not to function as a standalone diagnostic tool. It also says the final clinical decision remains the physician's responsibility, based on a comprehensive assessment. This limitation defines how the result should be used: as an aid within a medical assessment, not as an independent final judgment.
GE HealthCare says the two features have received clearance from the U.S. Food and Drug Administration and the European conformity mark, and that they are available for purchase through Vscan Air Innovation packages in the United States and selected markets. The commercial availability announced by the company is therefore tied to specific packages and markets, rather than being available in all markets, according to the statement. For existing customers, the company expects the updates to arrive by the end of November 2026 if they have a valid subscription or license for an Innovation package. The company thus ties access to the new features to license eligibility, with a stated timeline for existing customers. The announcement did not include a figure for the additions' impact on revenue or sales.
The additions join a set of cardiac and lung capabilities that already included, according to the company, Caption AI for guiding cardiac scans and Caption Interpretation Auto EF for supporting ejection fraction interpretation. The two new features expand the set to include lung scan guidance and an estimate of the likelihood of aortic stenosis. On financial performance, the company reported revenue of $5.5 billion in the third quarter ended September 30, 2026, up 7.2%, while organic revenue growth was 6.2%. On October 28, the company raised its 2026 organic revenue growth forecast to about 4%, from a previous range of 3% to 4%. Chief Executive Officer Peter Arduini said improved performance year to date and business momentum prompted the company to raise its outlook, while the stock closed at $84.03 on November 9, 2026.